drug	genes	question	answer	incorrect_recommendations	concurring_recommendation
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir?	Use abacavir per standard dosing guidelines	Avoid abacavir. Take an alternate therapy.|Take abacavir with a reduced dose.|Take abacavir with an increased dose.	Proceed taking abacavir as normal. There is no recommendation.
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir?	Abacavir is not recommended	Proceed taking abacavir as normal. There is no recommendation.|Take abacavir with a reduced dose.|Take abacavir with an increased dose.	Avoid abacavir. Take an alternate therapy.
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol?	Use allopurinol per standard dosing guidelines	Avoid allopurinol. Take an alternate therapy.|Take allopurinol with a reduced dose.|Take allopurinol with an increased dose.	Proceed taking allopurinol as normal. There is no recommendation.
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol?	Allopurinol is contraindicated	Proceed taking allopurinol as normal. There is no recommendation.|Take allopurinol with a reduced dose.|Take allopurinol with an increased dose.	Avoid allopurinol. Take an alternate therapy.
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking amikacin as normal. There is no recommendation.|Take amikacin with a reduced dose.|Take amikacin with an increased dose.	Avoid amikacin. Take an alternate therapy.
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid amikacin. Take an alternate therapy.|Take amikacin with a reduced dose.|Take amikacin with an increased dose.	Proceed taking amikacin as normal. There is no recommendation.
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid amikacin. Take an alternate therapy.|Take amikacin with a reduced dose.|Take amikacin with an increased dose.	Proceed taking amikacin as normal. There is no recommendation.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking gentamicin as normal. There is no recommendation.|Take gentamicin with a reduced dose.|Take gentamicin with an increased dose.	Avoid gentamicin. Take an alternate therapy.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid gentamicin. Take an alternate therapy.|Take gentamicin with a reduced dose.|Take gentamicin with an increased dose.	Proceed taking gentamicin as normal. There is no recommendation.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid gentamicin. Take an alternate therapy.|Take gentamicin with a reduced dose.|Take gentamicin with an increased dose.	Proceed taking gentamicin as normal. There is no recommendation.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking kanamycin as normal. There is no recommendation.|Take kanamycin with a reduced dose.|Take kanamycin with an increased dose.	Avoid kanamycin. Take an alternate therapy.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid kanamycin. Take an alternate therapy.|Take kanamycin with a reduced dose.|Take kanamycin with an increased dose.	Proceed taking kanamycin as normal. There is no recommendation.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid kanamycin. Take an alternate therapy.|Take kanamycin with a reduced dose.|Take kanamycin with an increased dose.	Proceed taking kanamycin as normal. There is no recommendation.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking paromomycin as normal. There is no recommendation.|Take paromomycin with a reduced dose.|Take paromomycin with an increased dose.	Avoid paromomycin. Take an alternate therapy.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid paromomycin. Take an alternate therapy.|Take paromomycin with a reduced dose.|Take paromomycin with an increased dose.	Proceed taking paromomycin as normal. There is no recommendation.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid paromomycin. Take an alternate therapy.|Take paromomycin with a reduced dose.|Take paromomycin with an increased dose.	Proceed taking paromomycin as normal. There is no recommendation.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking plazomicin as normal. There is no recommendation.|Take plazomicin with a reduced dose.|Take plazomicin with an increased dose.	Avoid plazomicin. Take an alternate therapy.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid plazomicin. Take an alternate therapy.|Take plazomicin with a reduced dose.|Take plazomicin with an increased dose.	Proceed taking plazomicin as normal. There is no recommendation.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid plazomicin. Take an alternate therapy.|Take plazomicin with a reduced dose.|Take plazomicin with an increased dose.	Proceed taking plazomicin as normal. There is no recommendation.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking streptomycin as normal. There is no recommendation.|Take streptomycin with a reduced dose.|Take streptomycin with an increased dose.	Avoid streptomycin. Take an alternate therapy.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid streptomycin. Take an alternate therapy.|Take streptomycin with a reduced dose.|Take streptomycin with an increased dose.	Proceed taking streptomycin as normal. There is no recommendation.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid streptomycin. Take an alternate therapy.|Take streptomycin with a reduced dose.|Take streptomycin with an increased dose.	Proceed taking streptomycin as normal. There is no recommendation.
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking tobramycin as normal. There is no recommendation.|Take tobramycin with a reduced dose.|Take tobramycin with an increased dose.	Avoid tobramycin. Take an alternate therapy.
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status	Avoid vitamin c. Take an alternate therapy.|Take vitamin c with a reduced dose.|Take vitamin c with an increased dose.	Proceed taking vitamin c as normal. There is no recommendation.
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid tobramycin. Take an alternate therapy.|Take tobramycin with a reduced dose.|Take tobramycin with an increased dose.	Proceed taking tobramycin as normal. There is no recommendation.
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid tobramycin. Take an alternate therapy.|Take tobramycin with a reduced dose.|Take tobramycin with an increased dose.	Proceed taking tobramycin as normal. There is no recommendation.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking dibekacin as normal. There is no recommendation.|Take dibekacin with a reduced dose.|Take dibekacin with an increased dose.	Avoid dibekacin. Take an alternate therapy.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid dibekacin. Take an alternate therapy.|Take dibekacin with a reduced dose.|Take dibekacin with an increased dose.	Proceed taking dibekacin as normal. There is no recommendation.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid dibekacin. Take an alternate therapy.|Take dibekacin with a reduced dose.|Take dibekacin with an increased dose.	Proceed taking dibekacin as normal. There is no recommendation.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking neomycin as normal. There is no recommendation.|Take neomycin with a reduced dose.|Take neomycin with an increased dose.	Avoid neomycin. Take an alternate therapy.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid neomycin. Take an alternate therapy.|Take neomycin with a reduced dose.|Take neomycin with an increased dose.	Proceed taking neomycin as normal. There is no recommendation.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid neomycin. Take an alternate therapy.|Take neomycin with a reduced dose.|Take neomycin with an increased dose.	Proceed taking neomycin as normal. There is no recommendation.
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking netilmicin as normal. There is no recommendation.|Take netilmicin with a reduced dose.|Take netilmicin with an increased dose.	Avoid netilmicin. Take an alternate therapy.
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid netilmicin. Take an alternate therapy.|Take netilmicin with a reduced dose.|Take netilmicin with an increased dose.	Proceed taking netilmicin as normal. There is no recommendation.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status at standard doses	Avoid dimercaprol. Take an alternate therapy.|Take dimercaprol with a reduced dose.|Take dimercaprol with an increased dose.	Proceed taking dimercaprol as normal. There is no recommendation.
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid netilmicin. Take an alternate therapy.|Take netilmicin with a reduced dose.|Take netilmicin with an increased dose.	Proceed taking netilmicin as normal. There is no recommendation.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Proceed taking ribostamycin as normal. There is no recommendation.|Take ribostamycin with a reduced dose.|Take ribostamycin with an increased dose.	Avoid ribostamycin. Take an alternate therapy.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid ribostamycin. Take an alternate therapy.|Take ribostamycin with a reduced dose.|Take ribostamycin with an increased dose.	Proceed taking ribostamycin as normal. There is no recommendation.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Avoid ribostamycin. Take an alternate therapy.|Take ribostamycin with a reduced dose.|Take ribostamycin with an increased dose.	Proceed taking ribostamycin as normal. There is no recommendation.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status	Avoid aminosalicylic acid. Take an alternate therapy.|Take aminosalicylic acid with a reduced dose.|Take aminosalicylic acid with an increased dose.	Proceed taking aminosalicylic acid as normal. There is no recommendation.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status at standard doses	Avoid aminosalicylic acid. Take an alternate therapy.|Take aminosalicylic acid with a reduced dose.|Take aminosalicylic acid with an increased dose.	Proceed taking aminosalicylic acid as normal. There is no recommendation.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid aminosalicylic acid. Take an alternate therapy.|Take aminosalicylic acid with a reduced dose.|Take aminosalicylic acid with an increased dose.	Proceed taking aminosalicylic acid as normal. There is no recommendation.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status at standard doses	Avoid aminosalicylic acid. Take an alternate therapy.|Take aminosalicylic acid with a reduced dose.|Take aminosalicylic acid with an increased dose.	Proceed taking aminosalicylic acid as normal. There is no recommendation.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid aminosalicylic acid. Take an alternate therapy.|Take aminosalicylic acid with a reduced dose.|Take aminosalicylic acid with an increased dose.	Proceed taking aminosalicylic acid as normal. There is no recommendation.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status	Avoid ciprofloxacin. Take an alternate therapy.|Take ciprofloxacin with a reduced dose.|Take ciprofloxacin with an increased dose.	Proceed taking ciprofloxacin as normal. There is no recommendation.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid ciprofloxacin. Take an alternate therapy.|Take ciprofloxacin with a reduced dose.|Take ciprofloxacin with an increased dose.	Proceed taking ciprofloxacin as normal. There is no recommendation.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid ciprofloxacin. Take an alternate therapy.|Take ciprofloxacin with a reduced dose.|Take ciprofloxacin with an increased dose.	Proceed taking ciprofloxacin as normal. There is no recommendation.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid ciprofloxacin. Take an alternate therapy.|Take ciprofloxacin with a reduced dose.|Take ciprofloxacin with an increased dose.	Proceed taking ciprofloxacin as normal. There is no recommendation.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid ciprofloxacin. Take an alternate therapy.|Take ciprofloxacin with a reduced dose.|Take ciprofloxacin with an increased dose.	Proceed taking ciprofloxacin as normal. There is no recommendation.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status	Avoid dimercaprol. Take an alternate therapy.|Take dimercaprol with a reduced dose.|Take dimercaprol with an increased dose.	Proceed taking dimercaprol as normal. There is no recommendation.
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status	Avoid mafenide. Take an alternate therapy.|Take mafenide with a reduced dose.|Take mafenide with an increased dose.	Proceed taking mafenide as normal. There is no recommendation.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid dimercaprol. Take an alternate therapy.|Take dimercaprol with a reduced dose.|Take dimercaprol with an increased dose.	Proceed taking dimercaprol as normal. There is no recommendation.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status at standard doses	Avoid dimercaprol. Take an alternate therapy.|Take dimercaprol with a reduced dose.|Take dimercaprol with an increased dose.	Proceed taking dimercaprol as normal. There is no recommendation.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid dimercaprol. Take an alternate therapy.|Take dimercaprol with a reduced dose.|Take dimercaprol with an increased dose.	Proceed taking dimercaprol as normal. There is no recommendation.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status	Avoid doxorubicin. Take an alternate therapy.|Take doxorubicin with a reduced dose.|Take doxorubicin with an increased dose.	Proceed taking doxorubicin as normal. There is no recommendation.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status at standard doses	Avoid doxorubicin. Take an alternate therapy.|Take doxorubicin with a reduced dose.|Take doxorubicin with an increased dose.	Proceed taking doxorubicin as normal. There is no recommendation.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid doxorubicin. Take an alternate therapy.|Take doxorubicin with a reduced dose.|Take doxorubicin with an increased dose.	Proceed taking doxorubicin as normal. There is no recommendation.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status at standard doses	Avoid doxorubicin. Take an alternate therapy.|Take doxorubicin with a reduced dose.|Take doxorubicin with an increased dose.	Proceed taking doxorubicin as normal. There is no recommendation.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid doxorubicin. Take an alternate therapy.|Take doxorubicin with a reduced dose.|Take doxorubicin with an increased dose.	Proceed taking doxorubicin as normal. There is no recommendation.
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status	Avoid furazolidone. Take an alternate therapy.|Take furazolidone with a reduced dose.|Take furazolidone with an increased dose.	Proceed taking furazolidone as normal. There is no recommendation.
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status at standard doses	Avoid furazolidone. Take an alternate therapy.|Take furazolidone with a reduced dose.|Take furazolidone with an increased dose.	Proceed taking furazolidone as normal. There is no recommendation.
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid furazolidone. Take an alternate therapy.|Take furazolidone with a reduced dose.|Take furazolidone with an increased dose.	Proceed taking furazolidone as normal. There is no recommendation.
furazolidone	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status at standard doses	Avoid furazolidone. Take an alternate therapy.|Take furazolidone with a reduced dose.|Take furazolidone with an increased dose.	Proceed taking furazolidone as normal. There is no recommendation.
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid furazolidone. Take an alternate therapy.|Take furazolidone with a reduced dose.|Take furazolidone with an increased dose.	Proceed taking furazolidone as normal. There is no recommendation.
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status	Avoid glyburide. Take an alternate therapy.|Take glyburide with a reduced dose.|Take glyburide with an increased dose.	Proceed taking glyburide as normal. There is no recommendation.
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status at standard doses	Avoid glyburide. Take an alternate therapy.|Take glyburide with a reduced dose.|Take glyburide with an increased dose.	Proceed taking glyburide as normal. There is no recommendation.
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid glyburide. Take an alternate therapy.|Take glyburide with a reduced dose.|Take glyburide with an increased dose.	Proceed taking glyburide as normal. There is no recommendation.
glyburide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status at standard doses	Avoid glyburide. Take an alternate therapy.|Take glyburide with a reduced dose.|Take glyburide with an increased dose.	Proceed taking glyburide as normal. There is no recommendation.
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid glyburide. Take an alternate therapy.|Take glyburide with a reduced dose.|Take glyburide with an increased dose.	Proceed taking glyburide as normal. There is no recommendation.
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status at standard doses	Avoid mafenide. Take an alternate therapy.|Take mafenide with a reduced dose.|Take mafenide with an increased dose.	Proceed taking mafenide as normal. There is no recommendation.
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid mafenide. Take an alternate therapy.|Take mafenide with a reduced dose.|Take mafenide with an increased dose.	Proceed taking mafenide as normal. There is no recommendation.
mafenide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status at standard doses	Avoid mafenide. Take an alternate therapy.|Take mafenide with a reduced dose.|Take mafenide with an increased dose.	Proceed taking mafenide as normal. There is no recommendation.
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid mafenide. Take an alternate therapy.|Take mafenide with a reduced dose.|Take mafenide with an increased dose.	Proceed taking mafenide as normal. There is no recommendation.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status	Avoid nalidixic acid. Take an alternate therapy.|Take nalidixic acid with a reduced dose.|Take nalidixic acid with an increased dose.	Proceed taking nalidixic acid as normal. There is no recommendation.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status at standard doses	Avoid nalidixic acid. Take an alternate therapy.|Take nalidixic acid with a reduced dose.|Take nalidixic acid with an increased dose.	Proceed taking nalidixic acid as normal. There is no recommendation.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid nalidixic acid. Take an alternate therapy.|Take nalidixic acid with a reduced dose.|Take nalidixic acid with an increased dose.	Proceed taking nalidixic acid as normal. There is no recommendation.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status at standard doses	Avoid nalidixic acid. Take an alternate therapy.|Take nalidixic acid with a reduced dose.|Take nalidixic acid with an increased dose.	Proceed taking nalidixic acid as normal. There is no recommendation.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid nalidixic acid. Take an alternate therapy.|Take nalidixic acid with a reduced dose.|Take nalidixic acid with an increased dose.	Proceed taking nalidixic acid as normal. There is no recommendation.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status	Avoid norfloxacin. Take an alternate therapy.|Take norfloxacin with a reduced dose.|Take norfloxacin with an increased dose.	Proceed taking norfloxacin as normal. There is no recommendation.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid norfloxacin. Take an alternate therapy.|Take norfloxacin with a reduced dose.|Take norfloxacin with an increased dose.	Proceed taking norfloxacin as normal. There is no recommendation.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid norfloxacin. Take an alternate therapy.|Take norfloxacin with a reduced dose.|Take norfloxacin with an increased dose.	Proceed taking norfloxacin as normal. There is no recommendation.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid norfloxacin. Take an alternate therapy.|Take norfloxacin with a reduced dose.|Take norfloxacin with an increased dose.	Proceed taking norfloxacin as normal. There is no recommendation.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid norfloxacin. Take an alternate therapy.|Take norfloxacin with a reduced dose.|Take norfloxacin with an increased dose.	Proceed taking norfloxacin as normal. There is no recommendation.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status	Avoid ofloxacin. Take an alternate therapy.|Take ofloxacin with a reduced dose.|Take ofloxacin with an increased dose.	Proceed taking ofloxacin as normal. There is no recommendation.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid ofloxacin. Take an alternate therapy.|Take ofloxacin with a reduced dose.|Take ofloxacin with an increased dose.	Proceed taking ofloxacin as normal. There is no recommendation.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid ofloxacin. Take an alternate therapy.|Take ofloxacin with a reduced dose.|Take ofloxacin with an increased dose.	Proceed taking ofloxacin as normal. There is no recommendation.
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status at standard doses	Avoid vitamin c. Take an alternate therapy.|Take vitamin c with a reduced dose.|Take vitamin c with an increased dose.	Proceed taking vitamin c as normal. There is no recommendation.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status at standard doses	Avoid ofloxacin. Take an alternate therapy.|Take ofloxacin with a reduced dose.|Take ofloxacin with an increased dose.	Proceed taking ofloxacin as normal. There is no recommendation.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid ofloxacin. Take an alternate therapy.|Take ofloxacin with a reduced dose.|Take ofloxacin with an increased dose.	Proceed taking ofloxacin as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status	Avoid quinine. Take an alternate therapy.|Take quinine with a reduced dose.|Take quinine with an increased dose.	Proceed taking quinine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status at standard doses	Avoid chloramphenicol. Take an alternate therapy.|Take chloramphenicol with a reduced dose.|Take chloramphenicol with an increased dose.	Proceed taking chloramphenicol as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid chloramphenicol. Take an alternate therapy.|Take chloramphenicol with a reduced dose.|Take chloramphenicol with an increased dose.	Proceed taking chloramphenicol as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status at standard doses	Avoid chloroquine. Take an alternate therapy.|Take chloroquine with a reduced dose.|Take chloroquine with an increased dose.	Proceed taking chloroquine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir?	No recommendation	Avoid atazanavir. Take an alternate therapy.|Take atazanavir with a reduced dose.|Take atazanavir with an increased dose.	Proceed taking atazanavir as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking azathioprine?	TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Avoid amitriptyline. Take an alternate therapy.	Take amitriptyline with an altered dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid chloroquine. Take an alternate therapy.|Take chloroquine with a reduced dose.|Take chloroquine with an increased dose.	Proceed taking chloroquine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status at standard doses	Avoid chloroquine. Take an alternate therapy.|Take chloroquine with a reduced dose.|Take chloroquine with an increased dose.	Proceed taking chloroquine as normal. There is no recommendation.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking amitriptyline as normal. There is no recommendation.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Avoid amitriptyline. Take an alternate therapy.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	No recommendation	Avoid amitriptyline. Take an alternate therapy.|Take amitriptyline with a reduced dose.|Take amitriptyline with an increased dose.	Proceed taking amitriptyline as normal. There is no recommendation.
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status	Avoid aspirin. Take an alternate therapy.|Take aspirin with a reduced dose.|Take aspirin with an increased dose.	Proceed taking aspirin as normal. There is no recommendation.
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status at standard doses	Avoid aspirin. Take an alternate therapy.|Take aspirin with a reduced dose.|Take aspirin with an increased dose.	Proceed taking aspirin as normal. There is no recommendation.
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid aspirin. Take an alternate therapy.|Take aspirin with a reduced dose.|Take aspirin with an increased dose.	Proceed taking aspirin as normal. There is no recommendation.
aspirin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status at standard doses	Avoid aspirin. Take an alternate therapy.|Take aspirin with a reduced dose.|Take aspirin with an increased dose.	Proceed taking aspirin as normal. There is no recommendation.
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid aspirin. Take an alternate therapy.|Take aspirin with a reduced dose.|Take aspirin with an increased dose.	Proceed taking aspirin as normal. There is no recommendation.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir?	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Avoid atazanavir. Take an alternate therapy.|Take atazanavir with a reduced dose.|Take atazanavir with an increased dose.	Proceed taking atazanavir as normal. There is no recommendation.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir?	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Avoid atazanavir. Take an alternate therapy.|Take atazanavir with a reduced dose.|Take atazanavir with an increased dose.	Proceed taking atazanavir as normal. There is no recommendation.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir?	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	Proceed taking atazanavir as normal. There is no recommendation.|Take atazanavir with a reduced dose.|Take atazanavir with an increased dose.	Avoid atazanavir. Take an alternate therapy.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine?	No recommendation	Avoid atomoxetine. Take an alternate therapy.|Take atomoxetine with a reduced dose.|Take atomoxetine with an increased dose.	Proceed taking atomoxetine as normal. There is no recommendation.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
chloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloroquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid chloroquine. Take an alternate therapy.|Take chloroquine with a reduced dose.|Take chloroquine with an increased dose.	Proceed taking chloroquine as normal. There is no recommendation.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status at standard doses	Avoid hydroxychloroquine. Take an alternate therapy.|Take hydroxychloroquine with a reduced dose.|Take hydroxychloroquine with an increased dose.	Proceed taking hydroxychloroquine as normal. There is no recommendation.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.	Proceed taking atomoxetine as normal. There is no recommendation.|Avoid atomoxetine. Take an alternate therapy.	Take atomoxetine with an altered dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine?	No recommendation	Avoid atomoxetine. Take an alternate therapy.|Take atomoxetine with a reduced dose.|Take atomoxetine with an increased dose.	Proceed taking atomoxetine as normal. There is no recommendation.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid atorvastatin. Take an alternate therapy.|Take atorvastatin with a reduced dose.|Take atorvastatin with an increased dose.	Proceed taking atorvastatin as normal. There is no recommendation.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid atorvastatin. Take an alternate therapy.|Take atorvastatin with a reduced dose.|Take atorvastatin with an increased dose.	Proceed taking atorvastatin as normal. There is no recommendation.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking atorvastatin as normal. There is no recommendation.|Avoid atorvastatin. Take an alternate therapy.	Take atorvastatin with an altered dose.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking atorvastatin as normal. There is no recommendation.|Avoid atorvastatin. Take an alternate therapy.	Take atorvastatin with an altered dose.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking atorvastatin as normal. There is no recommendation.|Avoid atorvastatin. Take an alternate therapy.	Take atorvastatin with an altered dose.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin?	No recommendation	Avoid atorvastatin. Take an alternate therapy.|Take atorvastatin with a reduced dose.|Take atorvastatin with an increased dose.	Proceed taking atorvastatin as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status at standard doses	Avoid hydroxychloroquine. Take an alternate therapy.|Take hydroxychloroquine with a reduced dose.|Take hydroxychloroquine with an increased dose.	Proceed taking hydroxychloroquine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid hydroxychloroquine. Take an alternate therapy.|Take hydroxychloroquine with a reduced dose.|Take hydroxychloroquine with an increased dose.	Proceed taking hydroxychloroquine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Proceed taking azathioprine as normal. There is no recommendation.|Avoid azathioprine. Take an alternate therapy.	Take azathioprine with an altered dose.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Avoid azathioprine. Take an alternate therapy.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Proceed taking azathioprine as normal. There is no recommendation.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking azathioprine as normal. There is no recommendation.|Take azathioprine with a reduced dose.|Take azathioprine with an increased dose.	Avoid azathioprine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.	Proceed taking carbamazepine as normal. There is no recommendation.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Avoid carbamazepine. Take an alternate therapy.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid flurbiprofen. Take an alternate therapy.|Take flurbiprofen with a reduced dose.|Take flurbiprofen with an increased dose.	Proceed taking flurbiprofen as normal. There is no recommendation.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking hydroxychloroquine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid hydroxychloroquine. Take an alternate therapy.|Take hydroxychloroquine with a reduced dose.|Take hydroxychloroquine with an increased dose.	Proceed taking hydroxychloroquine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.	Avoid carbamazepine. Take an alternate therapy.|Take carbamazepine with a reduced dose.|Take carbamazepine with an increased dose.	Proceed taking carbamazepine as normal. There is no recommendation.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid celecoxib. Take an alternate therapy.|Take celecoxib with a reduced dose.|Take celecoxib with an increased dose.	Proceed taking celecoxib as normal. There is no recommendation.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid celecoxib. Take an alternate therapy.|Take celecoxib with a reduced dose.|Take celecoxib with an increased dose.	Proceed taking celecoxib as normal. There is no recommendation.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	Avoid celecoxib. Take an alternate therapy.|Take celecoxib with a reduced dose.|Take celecoxib with an increased dose.	Proceed taking celecoxib as normal. There is no recommendation.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking celecoxib as normal. There is no recommendation.|Avoid celecoxib. Take an alternate therapy.	Take celecoxib with an altered dose.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking celecoxib as normal. There is no recommendation.|Avoid celecoxib. Take an alternate therapy.	Take celecoxib with an altered dose.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib?	No recommendation	Avoid celecoxib. Take an alternate therapy.|Take celecoxib with a reduced dose.|Take celecoxib with an increased dose.	Proceed taking celecoxib as normal. There is no recommendation.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid flurbiprofen. Take an alternate therapy.|Take flurbiprofen with a reduced dose.|Take flurbiprofen with an increased dose.	Proceed taking flurbiprofen as normal. There is no recommendation.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	Avoid flurbiprofen. Take an alternate therapy.|Take flurbiprofen with a reduced dose.|Take flurbiprofen with an increased dose.	Proceed taking flurbiprofen as normal. There is no recommendation.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking flurbiprofen as normal. There is no recommendation.|Avoid flurbiprofen. Take an alternate therapy.	Take flurbiprofen with an altered dose.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking flurbiprofen as normal. There is no recommendation.|Avoid flurbiprofen. Take an alternate therapy.	Take flurbiprofen with an altered dose.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen?	No recommendation	Avoid flurbiprofen. Take an alternate therapy.|Take flurbiprofen with a reduced dose.|Take flurbiprofen with an increased dose.	Proceed taking flurbiprofen as normal. There is no recommendation.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid ibuprofen. Take an alternate therapy.|Take ibuprofen with a reduced dose.|Take ibuprofen with an increased dose.	Proceed taking ibuprofen as normal. There is no recommendation.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid ibuprofen. Take an alternate therapy.|Take ibuprofen with a reduced dose.|Take ibuprofen with an increased dose.	Proceed taking ibuprofen as normal. There is no recommendation.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	Avoid ibuprofen. Take an alternate therapy.|Take ibuprofen with a reduced dose.|Take ibuprofen with an increased dose.	Proceed taking ibuprofen as normal. There is no recommendation.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking ibuprofen as normal. There is no recommendation.|Avoid ibuprofen. Take an alternate therapy.	Take ibuprofen with an altered dose.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking ibuprofen as normal. There is no recommendation.|Avoid ibuprofen. Take an alternate therapy.	Take ibuprofen with an altered dose.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen?	No recommendation	Avoid ibuprofen. Take an alternate therapy.|Take ibuprofen with a reduced dose.|Take ibuprofen with an increased dose.	Proceed taking ibuprofen as normal. There is no recommendation.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid lornoxicam. Take an alternate therapy.|Take lornoxicam with a reduced dose.|Take lornoxicam with an increased dose.	Proceed taking lornoxicam as normal. There is no recommendation.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid lornoxicam. Take an alternate therapy.|Take lornoxicam with a reduced dose.|Take lornoxicam with an increased dose.	Proceed taking lornoxicam as normal. There is no recommendation.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	Avoid lornoxicam. Take an alternate therapy.|Take lornoxicam with a reduced dose.|Take lornoxicam with an increased dose.	Proceed taking lornoxicam as normal. There is no recommendation.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking lornoxicam as normal. There is no recommendation.|Avoid lornoxicam. Take an alternate therapy.	Take lornoxicam with an altered dose.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Proceed taking lornoxicam as normal. There is no recommendation.|Avoid lornoxicam. Take an alternate therapy.	Take lornoxicam with an altered dose.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam?	No recommendation	Avoid lornoxicam. Take an alternate therapy.|Take lornoxicam with a reduced dose.|Take lornoxicam with an increased dose.	Proceed taking lornoxicam as normal. There is no recommendation.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status	Avoid chloramphenicol. Take an alternate therapy.|Take chloramphenicol with a reduced dose.|Take chloramphenicol with an increased dose.	Proceed taking chloramphenicol as normal. There is no recommendation.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status at standard doses	Avoid chloramphenicol. Take an alternate therapy.|Take chloramphenicol with a reduced dose.|Take chloramphenicol with an increased dose.	Proceed taking chloramphenicol as normal. There is no recommendation.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid chloramphenicol. Take an alternate therapy.|Take chloramphenicol with a reduced dose.|Take chloramphenicol with an increased dose.	Proceed taking chloramphenicol as normal. There is no recommendation.
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status	Avoid chloroquine. Take an alternate therapy.|Take chloroquine with a reduced dose.|Take chloroquine with an increased dose.	Proceed taking chloroquine as normal. There is no recommendation.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status	Avoid hydroxychloroquine. Take an alternate therapy.|Take hydroxychloroquine with a reduced dose.|Take hydroxychloroquine with an increased dose.	Proceed taking hydroxychloroquine as normal. There is no recommendation.
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid vitamin c. Take an alternate therapy.|Take vitamin c with a reduced dose.|Take vitamin c with an increased dose.	Proceed taking vitamin c as normal. There is no recommendation.
vitamin c	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status at standard doses	Avoid vitamin c. Take an alternate therapy.|Take vitamin c with a reduced dose.|Take vitamin c with an increased dose.	Proceed taking vitamin c as normal. There is no recommendation.
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid vitamin c. Take an alternate therapy.|Take vitamin c with a reduced dose.|Take vitamin c with an increased dose.	Proceed taking vitamin c as normal. There is no recommendation.
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status	Avoid vitamin k. Take an alternate therapy.|Take vitamin k with a reduced dose.|Take vitamin k with an increased dose.	Proceed taking vitamin k as normal. There is no recommendation.
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status at standard doses	Avoid vitamin k. Take an alternate therapy.|Take vitamin k with a reduced dose.|Take vitamin k with an increased dose.	Proceed taking vitamin k as normal. There is no recommendation.
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid vitamin k. Take an alternate therapy.|Take vitamin k with a reduced dose.|Take vitamin k with an increased dose.	Proceed taking vitamin k as normal. There is no recommendation.
vitamin k	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status at standard doses	Avoid vitamin k. Take an alternate therapy.|Take vitamin k with a reduced dose.|Take vitamin k with an increased dose.	Proceed taking vitamin k as normal. There is no recommendation.
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid vitamin k. Take an alternate therapy.|Take vitamin k with a reduced dose.|Take vitamin k with an increased dose.	Proceed taking vitamin k as normal. There is no recommendation.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Proceed taking citalopram as normal. There is no recommendation.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Avoid citalopram. Take an alternate therapy.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Avoid citalopram. Take an alternate therapy.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Proceed taking citalopram as normal. There is no recommendation.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose	Avoid citalopram. Take an alternate therapy.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Proceed taking citalopram as normal. There is no recommendation.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid citalopram. Take an alternate therapy.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Proceed taking citalopram as normal. There is no recommendation.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid citalopram. Take an alternate therapy.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Proceed taking citalopram as normal. There is no recommendation.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Proceed taking citalopram as normal. There is no recommendation.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Avoid citalopram. Take an alternate therapy.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Proceed taking citalopram as normal. There is no recommendation.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Avoid citalopram. Take an alternate therapy.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram?	No recommendation	Avoid citalopram. Take an alternate therapy.|Take citalopram with a reduced dose.|Take citalopram with an increased dose.	Proceed taking citalopram as normal. There is no recommendation.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Proceed taking escitalopram as normal. There is no recommendation.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Avoid escitalopram. Take an alternate therapy.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Avoid escitalopram. Take an alternate therapy.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Proceed taking escitalopram as normal. There is no recommendation.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose	Avoid escitalopram. Take an alternate therapy.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Proceed taking escitalopram as normal. There is no recommendation.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid escitalopram. Take an alternate therapy.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Proceed taking escitalopram as normal. There is no recommendation.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid escitalopram. Take an alternate therapy.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Proceed taking escitalopram as normal. There is no recommendation.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Proceed taking escitalopram as normal. There is no recommendation.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Avoid escitalopram. Take an alternate therapy.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Proceed taking escitalopram as normal. There is no recommendation.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Avoid escitalopram. Take an alternate therapy.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram?	No recommendation	Avoid escitalopram. Take an alternate therapy.|Take escitalopram with a reduced dose.|Take escitalopram with an increased dose.	Proceed taking escitalopram as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam?	No recommendation	Avoid tenoxicam. Take an alternate therapy.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Proceed taking tenoxicam as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Avoid clomipramine. Take an alternate therapy.	Take clomipramine with an altered dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.	Avoid clomipramine. Take an alternate therapy.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Proceed taking clomipramine as normal. There is no recommendation.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking clomipramine as normal. There is no recommendation.|Take clomipramine with a reduced dose.|Take clomipramine with an increased dose.	Avoid clomipramine. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone?	Avoid use	Proceed taking dapsone as normal. There is no recommendation.|Take dapsone with a reduced dose.|Take dapsone with an increased dose.	Avoid dapsone. Take an alternate therapy.
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone?	Avoid use	Proceed taking dapsone as normal. There is no recommendation.|Take dapsone with a reduced dose.|Take dapsone with an increased dose.	Avoid dapsone. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.	Proceed taking clopidogrel as normal. There is no recommendation.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Avoid clopidogrel. Take an alternate therapy.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation	Avoid clopidogrel. Take an alternate therapy.|Take clopidogrel with a reduced dose.|Take clopidogrel with an increased dose.	Proceed taking clopidogrel as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking codeine?	No recommendation	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.	Avoid codeine. Take an alternate therapy.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Proceed taking codeine as normal. There is no recommendation.
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Proceed taking codeine as normal. There is no recommendation.|Take codeine with a reduced dose.|Take codeine with an increased dose.	Avoid codeine. Take an alternate therapy.
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone?	No reason to avoid based on G6PD status	Avoid dapsone. Take an alternate therapy.|Take dapsone with a reduced dose.|Take dapsone with an increased dose.	Proceed taking dapsone as normal. There is no recommendation.
dapsone	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking dapsone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid dapsone. Take an alternate therapy.|Take dapsone with a reduced dose.|Take dapsone with an increased dose.	Proceed taking dapsone as normal. There is no recommendation.
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid dapsone. Take an alternate therapy.|Take dapsone with a reduced dose.|Take dapsone with an increased dose.	Proceed taking dapsone as normal. There is no recommendation.
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase?	No reason to avoid based on G6PD status	Avoid pegloticase. Take an alternate therapy.|Take pegloticase with a reduced dose.|Take pegloticase with an increased dose.	Proceed taking pegloticase as normal. There is no recommendation.
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase?	Avoid use	Proceed taking pegloticase as normal. There is no recommendation.|Take pegloticase with a reduced dose.|Take pegloticase with an increased dose.	Avoid pegloticase. Take an alternate therapy.
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase?	Avoid use	Proceed taking pegloticase as normal. There is no recommendation.|Take pegloticase with a reduced dose.|Take pegloticase with an increased dose.	Avoid pegloticase. Take an alternate therapy.
pegloticase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking pegloticase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid pegloticase. Take an alternate therapy.|Take pegloticase with a reduced dose.|Take pegloticase with an increased dose.	Proceed taking pegloticase as normal. There is no recommendation.
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid pegloticase. Take an alternate therapy.|Take pegloticase with a reduced dose.|Take pegloticase with an increased dose.	Proceed taking pegloticase as normal. There is no recommendation.
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase?	No reason to avoid based on G6PD status	Avoid rasburicase. Take an alternate therapy.|Take rasburicase with a reduced dose.|Take rasburicase with an increased dose.	Proceed taking rasburicase as normal. There is no recommendation.
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase?	Avoid use	Proceed taking rasburicase as normal. There is no recommendation.|Take rasburicase with a reduced dose.|Take rasburicase with an increased dose.	Avoid rasburicase. Take an alternate therapy.
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase?	Avoid use	Proceed taking rasburicase as normal. There is no recommendation.|Take rasburicase with a reduced dose.|Take rasburicase with an increased dose.	Avoid rasburicase. Take an alternate therapy.
rasburicase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking rasburicase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid rasburicase. Take an alternate therapy.|Take rasburicase with a reduced dose.|Take rasburicase with an increased dose.	Proceed taking rasburicase as normal. There is no recommendation.
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid rasburicase. Take an alternate therapy.|Take rasburicase with a reduced dose.|Take rasburicase with an increased dose.	Proceed taking rasburicase as normal. There is no recommendation.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking desflurane as normal. There is no recommendation.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Avoid desflurane. Take an alternate therapy.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid desflurane. Take an alternate therapy.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Proceed taking desflurane as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking desflurane as normal. There is no recommendation.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Avoid desflurane. Take an alternate therapy.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid desflurane. Take an alternate therapy.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Proceed taking desflurane as normal. There is no recommendation.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking desflurane as normal. There is no recommendation.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Avoid desflurane. Take an alternate therapy.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking desflurane as normal. There is no recommendation.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Avoid desflurane. Take an alternate therapy.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking desflurane as normal. There is no recommendation.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Avoid desflurane. Take an alternate therapy.
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status at standard doses	Avoid quinine. Take an alternate therapy.|Take quinine with a reduced dose.|Take quinine with an increased dose.	Proceed taking quinine as normal. There is no recommendation.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid desflurane. Take an alternate therapy.|Take desflurane with a reduced dose.|Take desflurane with an increased dose.	Proceed taking desflurane as normal. There is no recommendation.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking enflurane as normal. There is no recommendation.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Avoid enflurane. Take an alternate therapy.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking enflurane as normal. There is no recommendation.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Avoid enflurane. Take an alternate therapy.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid enflurane. Take an alternate therapy.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Proceed taking enflurane as normal. There is no recommendation.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking enflurane as normal. There is no recommendation.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Avoid enflurane. Take an alternate therapy.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid halothane. Take an alternate therapy.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Proceed taking halothane as normal. There is no recommendation.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking enflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking enflurane as normal. There is no recommendation.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Avoid enflurane. Take an alternate therapy.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking enflurane as normal. There is no recommendation.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Avoid enflurane. Take an alternate therapy.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking enflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid enflurane. Take an alternate therapy.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Proceed taking enflurane as normal. There is no recommendation.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid enflurane. Take an alternate therapy.|Take enflurane with a reduced dose.|Take enflurane with an increased dose.	Proceed taking enflurane as normal. There is no recommendation.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking halothane as normal. There is no recommendation.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Avoid halothane. Take an alternate therapy.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid halothane. Take an alternate therapy.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Proceed taking halothane as normal. There is no recommendation.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid sevoflurane. Take an alternate therapy.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Proceed taking sevoflurane as normal. There is no recommendation.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking halothane as normal. There is no recommendation.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Avoid halothane. Take an alternate therapy.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid halothane. Take an alternate therapy.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Proceed taking halothane as normal. There is no recommendation.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking halothane as normal. There is no recommendation.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Avoid halothane. Take an alternate therapy.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking halothane as normal. There is no recommendation.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Avoid halothane. Take an alternate therapy.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking halothane as normal. There is no recommendation.|Take halothane with a reduced dose.|Take halothane with an increased dose.	Avoid halothane. Take an alternate therapy.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.|Take sulfamethoxazole / trimethoprim with a reduced dose.|Take sulfamethoxazole / trimethoprim with an increased dose.	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking isoflurane as normal. There is no recommendation.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Avoid isoflurane. Take an alternate therapy.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking isoflurane as normal. There is no recommendation.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Avoid isoflurane. Take an alternate therapy.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid isoflurane. Take an alternate therapy.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Proceed taking isoflurane as normal. There is no recommendation.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking isoflurane as normal. There is no recommendation.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Avoid isoflurane. Take an alternate therapy.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking isoflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking isoflurane as normal. There is no recommendation.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Avoid isoflurane. Take an alternate therapy.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking isoflurane as normal. There is no recommendation.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Avoid isoflurane. Take an alternate therapy.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking isoflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid isoflurane. Take an alternate therapy.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Proceed taking isoflurane as normal. There is no recommendation.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid isoflurane. Take an alternate therapy.|Take isoflurane with a reduced dose.|Take isoflurane with an increased dose.	Proceed taking isoflurane as normal. There is no recommendation.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking methoxyflurane as normal. There is no recommendation.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Avoid methoxyflurane. Take an alternate therapy.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking methoxyflurane as normal. There is no recommendation.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Avoid methoxyflurane. Take an alternate therapy.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid methoxyflurane. Take an alternate therapy.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Proceed taking methoxyflurane as normal. There is no recommendation.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status at standard doses	Avoid sulfanilamide. Take an alternate therapy.|Take sulfanilamide with a reduced dose.|Take sulfanilamide with an increased dose.	Proceed taking sulfanilamide as normal. There is no recommendation.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking methoxyflurane as normal. There is no recommendation.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Avoid methoxyflurane. Take an alternate therapy.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking methoxyflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking methoxyflurane as normal. There is no recommendation.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Avoid methoxyflurane. Take an alternate therapy.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking methoxyflurane as normal. There is no recommendation.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Avoid methoxyflurane. Take an alternate therapy.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking methoxyflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid methoxyflurane. Take an alternate therapy.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Proceed taking methoxyflurane as normal. There is no recommendation.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid methoxyflurane. Take an alternate therapy.|Take methoxyflurane with a reduced dose.|Take methoxyflurane with an increased dose.	Proceed taking methoxyflurane as normal. There is no recommendation.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking sevoflurane as normal. There is no recommendation.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Avoid sevoflurane. Take an alternate therapy.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking sevoflurane as normal. There is no recommendation.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Avoid sevoflurane. Take an alternate therapy.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking sevoflurane as normal. There is no recommendation.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Avoid sevoflurane. Take an alternate therapy.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid sevoflurane. Take an alternate therapy.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Proceed taking sevoflurane as normal. There is no recommendation.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking sevoflurane as normal. There is no recommendation.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Avoid sevoflurane. Take an alternate therapy.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking sevoflurane as normal. There is no recommendation.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Avoid sevoflurane. Take an alternate therapy.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid sevoflurane. Take an alternate therapy.|Take sevoflurane with a reduced dose.|Take sevoflurane with an increased dose.	Proceed taking sevoflurane as normal. There is no recommendation.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking succinylcholine as normal. There is no recommendation.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Avoid succinylcholine. Take an alternate therapy.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking succinylcholine as normal. There is no recommendation.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Avoid succinylcholine. Take an alternate therapy.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid succinylcholine. Take an alternate therapy.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Proceed taking succinylcholine as normal. There is no recommendation.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking succinylcholine as normal. There is no recommendation.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Avoid succinylcholine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking succinylcholine?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking succinylcholine as normal. There is no recommendation.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Avoid succinylcholine. Take an alternate therapy.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Proceed taking succinylcholine as normal. There is no recommendation.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Avoid succinylcholine. Take an alternate therapy.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking succinylcholine?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid succinylcholine. Take an alternate therapy.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Proceed taking succinylcholine as normal. There is no recommendation.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Avoid succinylcholine. Take an alternate therapy.|Take succinylcholine with a reduced dose.|Take succinylcholine with an increased dose.	Proceed taking succinylcholine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid tolbutamide. Take an alternate therapy.|Take tolbutamide with a reduced dose.|Take tolbutamide with an increased dose.	Proceed taking tolbutamide as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Avoid desipramine. Take an alternate therapy.	Take desipramine with an altered dose.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Avoid desipramine. Take an alternate therapy.	Take desipramine with an altered dose.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Avoid desipramine. Take an alternate therapy.	Take desipramine with an altered dose.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Avoid desipramine. Take an alternate therapy.	Take desipramine with an altered dose.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking desipramine as normal. There is no recommendation.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Avoid desipramine. Take an alternate therapy.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking desipramine?	No recommendation	Avoid desipramine. Take an alternate therapy.|Take desipramine with a reduced dose.|Take desipramine with an increased dose.	Proceed taking desipramine as normal. There is no recommendation.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking dexlansoprazole as normal. There is no recommendation.|Avoid dexlansoprazole. Take an alternate therapy.	Take dexlansoprazole with an altered dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole?	No recommendation	Avoid dexlansoprazole. Take an alternate therapy.|Take dexlansoprazole with a reduced dose.|Take dexlansoprazole with an increased dose.	Proceed taking dexlansoprazole as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid lovastatin. Take an alternate therapy.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Proceed taking lovastatin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Avoid doxepin. Take an alternate therapy.	Take doxepin with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine?	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	Avoid capecitabine. Take an alternate therapy.|Take capecitabine with a reduced dose.|Take capecitabine with an increased dose.	Proceed taking capecitabine as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	Proceed taking capecitabine as normal. There is no recommendation.|Avoid capecitabine. Take an alternate therapy.	Take capecitabine with an altered dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.	Avoid doxepin. Take an alternate therapy.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Proceed taking doxepin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking doxepin as normal. There is no recommendation.|Take doxepin with a reduced dose.|Take doxepin with an increased dose.	Avoid doxepin. Take an alternate therapy.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)	Avoid efavirenz. Take an alternate therapy.|Take efavirenz with a reduced dose.|Take efavirenz with an increased dose.	Proceed taking efavirenz as normal. There is no recommendation.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)	Avoid efavirenz. Take an alternate therapy.|Take efavirenz with a reduced dose.|Take efavirenz with an increased dose.	Proceed taking efavirenz as normal. There is no recommendation.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)	Avoid efavirenz. Take an alternate therapy.|Take efavirenz with a reduced dose.|Take efavirenz with an increased dose.	Proceed taking efavirenz as normal. There is no recommendation.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 with regards to taking efavirenz?	Consider initiating efavirenz with decreased dose of 400 mg/day	Proceed taking efavirenz as normal. There is no recommendation.|Avoid efavirenz. Take an alternate therapy.	Take efavirenz with an altered dose.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 with regards to taking efavirenz?	Consider initiating efavirenz with decreased dose of 400 or 200 mg/day	Proceed taking efavirenz as normal. There is no recommendation.|Avoid efavirenz. Take an alternate therapy.	Take efavirenz with an altered dose.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz?	No recommendation	Avoid efavirenz. Take an alternate therapy.|Take efavirenz with a reduced dose.|Take efavirenz with an increased dose.	Proceed taking efavirenz as normal. There is no recommendation.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil?	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	Avoid fluorouracil. Take an alternate therapy.|Take fluorouracil with a reduced dose.|Take fluorouracil with an increased dose.	Proceed taking fluorouracil as normal. There is no recommendation.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	Proceed taking fluorouracil as normal. There is no recommendation.|Avoid fluorouracil. Take an alternate therapy.	Take fluorouracil with an altered dose.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	Proceed taking fluorouracil as normal. There is no recommendation.|Avoid fluorouracil. Take an alternate therapy.	Take fluorouracil with an altered dose.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking fluorouracil?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.	Proceed taking fluorouracil as normal. There is no recommendation.|Take fluorouracil with a reduced dose.|Take fluorouracil with an increased dose.	Avoid fluorouracil. Take an alternate therapy.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Proceed taking fluorouracil as normal. There is no recommendation.|Take fluorouracil with a reduced dose.|Take fluorouracil with an increased dose.	Avoid fluorouracil. Take an alternate therapy.
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	Proceed taking capecitabine as normal. There is no recommendation.|Avoid capecitabine. Take an alternate therapy.	Take capecitabine with an altered dose.
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking capecitabine?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.	Proceed taking capecitabine as normal. There is no recommendation.|Take capecitabine with a reduced dose.|Take capecitabine with an increased dose.	Avoid capecitabine. Take an alternate therapy.
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Proceed taking capecitabine as normal. There is no recommendation.|Take capecitabine with a reduced dose.|Take capecitabine with an increased dose.	Avoid capecitabine. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking fluvastatin as normal. There is no recommendation.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Avoid fluvastatin. Take an alternate therapy.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	n/a	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	n/a	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	n/a	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 genotype result is not available.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	Avoid fluvastatin. Take an alternate therapy.|Take fluvastatin with a reduced dose.|Take fluvastatin with an increased dose.	Proceed taking fluvastatin as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Proceed taking fluvastatin as normal. There is no recommendation.|Avoid fluvastatin. Take an alternate therapy.	Take fluvastatin with an altered dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking fluvoxamine?	Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Proceed taking fluvoxamine as normal. There is no recommendation.|Avoid fluvoxamine. Take an alternate therapy.	Take fluvoxamine with an altered dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking fluvoxamine?	No recommendation	Avoid fluvoxamine. Take an alternate therapy.|Take fluvoxamine with a reduced dose.|Take fluvoxamine with an increased dose.	Proceed taking fluvoxamine as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking hydrocodone?	No recommendation	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Avoid hydrocodone. Take an alternate therapy.|Take hydrocodone with a reduced dose.|Take hydrocodone with an increased dose.	Proceed taking hydrocodone as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status at standard doses	Avoid phenazopyridine. Take an alternate therapy.|Take phenazopyridine with a reduced dose.|Take phenazopyridine with an increased dose.	Proceed taking phenazopyridine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No recommendation	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	No recommendation	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid lovastatin. Take an alternate therapy.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Proceed taking lovastatin as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Avoid imipramine. Take an alternate therapy.	Take imipramine with an altered dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking imipramine as normal. There is no recommendation.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Avoid imipramine. Take an alternate therapy.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	No recommendation	Avoid imipramine. Take an alternate therapy.|Take imipramine with a reduced dose.|Take imipramine with an increased dose.	Proceed taking imipramine as normal. There is no recommendation.
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor?	Ivacaftor is not recommended	Proceed taking ivacaftor as normal. There is no recommendation.|Take ivacaftor with a reduced dose.|Take ivacaftor with an increased dose.	Avoid ivacaftor. Take an alternate therapy.
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor?	Use ivacaftor according to the product label	Avoid ivacaftor. Take an alternate therapy.|Take ivacaftor with a reduced dose.|Take ivacaftor with an increased dose.	Proceed taking ivacaftor as normal. There is no recommendation.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	Proceed taking lovastatin as normal. There is no recommendation.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Avoid lovastatin. Take an alternate therapy.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	Proceed taking lovastatin as normal. There is no recommendation.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Avoid lovastatin. Take an alternate therapy.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking lovastatin as normal. There is no recommendation.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Avoid lovastatin. Take an alternate therapy.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin?	No recommendation	Avoid lovastatin. Take an alternate therapy.|Take lovastatin with a reduced dose.|Take lovastatin with an increased dose.	Proceed taking lovastatin as normal. There is no recommendation.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid meloxicam. Take an alternate therapy.|Take meloxicam with a reduced dose.|Take meloxicam with an increased dose.	Proceed taking meloxicam as normal. There is no recommendation.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid meloxicam. Take an alternate therapy.|Take meloxicam with a reduced dose.|Take meloxicam with an increased dose.	Proceed taking meloxicam as normal. There is no recommendation.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking meloxicam as normal. There is no recommendation.|Avoid meloxicam. Take an alternate therapy.	Take meloxicam with an altered dose.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking meloxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking meloxicam as normal. There is no recommendation.|Take meloxicam with a reduced dose.|Take meloxicam with an increased dose.	Avoid meloxicam. Take an alternate therapy.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking meloxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking meloxicam as normal. There is no recommendation.|Take meloxicam with a reduced dose.|Take meloxicam with an increased dose.	Avoid meloxicam. Take an alternate therapy.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam?	No recommendation	Avoid meloxicam. Take an alternate therapy.|Take meloxicam with a reduced dose.|Take meloxicam with an increased dose.	Proceed taking meloxicam as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid mercaptopurine. Take an alternate therapy.|Take mercaptopurine with a reduced dose.|Take mercaptopurine with an increased dose.	Proceed taking mercaptopurine as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking mercaptopurine as normal. There is no recommendation.|Avoid mercaptopurine. Take an alternate therapy.	Take mercaptopurine with an altered dose.
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue?	No reason to avoid ased on G6PD status	Avoid methylene blue. Take an alternate therapy.|Take methylene blue with a reduced dose.|Take methylene blue with an increased dose.	Proceed taking methylene blue as normal. There is no recommendation.
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue?	Avoid use	Proceed taking methylene blue as normal. There is no recommendation.|Take methylene blue with a reduced dose.|Take methylene blue with an increased dose.	Avoid methylene blue. Take an alternate therapy.
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue?	Avoid use	Proceed taking methylene blue as normal. There is no recommendation.|Take methylene blue with a reduced dose.|Take methylene blue with an increased dose.	Avoid methylene blue. Take an alternate therapy.
methylene blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking methylene blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid methylene blue. Take an alternate therapy.|Take methylene blue with a reduced dose.|Take methylene blue with an increased dose.	Proceed taking methylene blue as normal. There is no recommendation.
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid methylene blue. Take an alternate therapy.|Take methylene blue with a reduced dose.|Take methylene blue with an increased dose.	Proceed taking methylene blue as normal. There is no recommendation.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin?	No reason to avoid based on G6PD status	Avoid nitrofurantoin. Take an alternate therapy.|Take nitrofurantoin with a reduced dose.|Take nitrofurantoin with an increased dose.	Proceed taking nitrofurantoin as normal. There is no recommendation.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin?	Use at standard doses with caution and with close monitoring for anemia	Avoid nitrofurantoin. Take an alternate therapy.|Take nitrofurantoin with a reduced dose.|Take nitrofurantoin with an increased dose.	Proceed taking nitrofurantoin as normal. There is no recommendation.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin?	Avoid	Proceed taking nitrofurantoin as normal. There is no recommendation.|Take nitrofurantoin with a reduced dose.|Take nitrofurantoin with an increased dose.	Avoid nitrofurantoin. Take an alternate therapy.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking nitrofurantoin?	If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid nitrofurantoin. Take an alternate therapy.|Take nitrofurantoin with a reduced dose.|Take nitrofurantoin with an increased dose.	Proceed taking nitrofurantoin as normal. There is no recommendation.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid nitrofurantoin. Take an alternate therapy.|Take nitrofurantoin with a reduced dose.|Take nitrofurantoin with an increased dose.	Proceed taking nitrofurantoin as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid phenazopyridine. Take an alternate therapy.|Take phenazopyridine with a reduced dose.|Take phenazopyridine with an increased dose.	Proceed taking phenazopyridine as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Avoid nortriptyline. Take an alternate therapy.	Take nortriptyline with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Avoid nortriptyline. Take an alternate therapy.	Take nortriptyline with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Avoid nortriptyline. Take an alternate therapy.	Take nortriptyline with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Avoid nortriptyline. Take an alternate therapy.	Take nortriptyline with an altered dose.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking nortriptyline as normal. There is no recommendation.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Avoid nortriptyline. Take an alternate therapy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking nortriptyline?	No recommendation	Avoid nortriptyline. Take an alternate therapy.|Take nortriptyline with a reduced dose.|Take nortriptyline with an increased dose.	Proceed taking nortriptyline as normal. There is no recommendation.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking omeprazole as normal. There is no recommendation.|Avoid omeprazole. Take an alternate therapy.	Take omeprazole with an altered dose.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole?	No recommendation	Avoid omeprazole. Take an alternate therapy.|Take omeprazole with a reduced dose.|Take omeprazole with an increased dose.	Proceed taking omeprazole as normal. There is no recommendation.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking lansoprazole as normal. There is no recommendation.|Avoid lansoprazole. Take an alternate therapy.	Take lansoprazole with an altered dose.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole?	No recommendation	Avoid lansoprazole. Take an alternate therapy.|Take lansoprazole with a reduced dose.|Take lansoprazole with an increased dose.	Proceed taking lansoprazole as normal. There is no recommendation.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Proceed taking pantoprazole as normal. There is no recommendation.|Avoid pantoprazole. Take an alternate therapy.	Take pantoprazole with an altered dose.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole?	No recommendation	Avoid pantoprazole. Take an alternate therapy.|Take pantoprazole with a reduced dose.|Take pantoprazole with an increased dose.	Proceed taking pantoprazole as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking ondansetron as normal. There is no recommendation.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Avoid ondansetron. Take an alternate therapy.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking ondansetron?	No recommendation	Avoid ondansetron. Take an alternate therapy.|Take ondansetron with a reduced dose.|Take ondansetron with an increased dose.	Proceed taking ondansetron as normal. There is no recommendation.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status at standard doses	Avoid phenazopyridine. Take an alternate therapy.|Take phenazopyridine with a reduced dose.|Take phenazopyridine with an increased dose.	Proceed taking phenazopyridine as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Proceed taking tropisetron as normal. There is no recommendation.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Avoid tropisetron. Take an alternate therapy.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tropisetron?	No recommendation	Avoid tropisetron. Take an alternate therapy.|Take tropisetron with a reduced dose.|Take tropisetron with an increased dose.	Proceed taking tropisetron as normal. There is no recommendation.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine?	Use oxcarbazepine per standard dosing guidelines.	Avoid oxcarbazepine. Take an alternate therapy.|Take oxcarbazepine with a reduced dose.|Take oxcarbazepine with an increased dose.	Proceed taking oxcarbazepine as normal. There is no recommendation.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine?	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	Proceed taking oxcarbazepine as normal. There is no recommendation.|Take oxcarbazepine with a reduced dose.|Take oxcarbazepine with an increased dose.	Avoid oxcarbazepine. Take an alternate therapy.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine?	Use oxcarbazepine per standard dosing guidelines.	Avoid oxcarbazepine. Take an alternate therapy.|Take oxcarbazepine with a reduced dose.|Take oxcarbazepine with an increased dose.	Proceed taking oxcarbazepine as normal. There is no recommendation.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	Avoid oxcarbazepine. Take an alternate therapy.|Take oxcarbazepine with a reduced dose.|Take oxcarbazepine with an increased dose.	Proceed taking oxcarbazepine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking phenazopyridine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid phenazopyridine. Take an alternate therapy.|Take phenazopyridine with a reduced dose.|Take phenazopyridine with an increased dose.	Proceed taking phenazopyridine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.	Proceed taking paroxetine as normal. There is no recommendation.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Avoid paroxetine. Take an alternate therapy.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Proceed taking paroxetine as normal. There is no recommendation.|Avoid paroxetine. Take an alternate therapy.	Take paroxetine with an altered dose.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Proceed taking paroxetine as normal. There is no recommendation.|Avoid paroxetine. Take an alternate therapy.	Take paroxetine with an altered dose.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Proceed taking paroxetine as normal. There is no recommendation.|Avoid paroxetine. Take an alternate therapy.	Take paroxetine with an altered dose.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Proceed taking paroxetine as normal. There is no recommendation.|Avoid paroxetine. Take an alternate therapy.	Take paroxetine with an altered dose.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking paroxetine?	Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.	Proceed taking paroxetine as normal. There is no recommendation.|Avoid paroxetine. Take an alternate therapy.	Take paroxetine with an altered dose.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking paroxetine?	No recommendation	Avoid paroxetine. Take an alternate therapy.|Take paroxetine with a reduced dose.|Take paroxetine with an increased dose.	Proceed taking paroxetine as normal. There is no recommendation.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status	Avoid phenazopyridine. Take an alternate therapy.|Take phenazopyridine with a reduced dose.|Take phenazopyridine with an increased dose.	Proceed taking phenazopyridine as normal. There is no recommendation.
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid quinine. Take an alternate therapy.|Take quinine with a reduced dose.|Take quinine with an increased dose.	Proceed taking quinine as normal. There is no recommendation.
quinine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status at standard doses	Avoid quinine. Take an alternate therapy.|Take quinine with a reduced dose.|Take quinine with an increased dose.	Proceed taking quinine as normal. There is no recommendation.
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid quinine. Take an alternate therapy.|Take quinine with a reduced dose.|Take quinine with an increased dose.	Proceed taking quinine as normal. There is no recommendation.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status	Avoid sulfadiazine. Take an alternate therapy.|Take sulfadiazine with a reduced dose.|Take sulfadiazine with an increased dose.	Proceed taking sulfadiazine as normal. There is no recommendation.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfadiazine. Take an alternate therapy.|Take sulfadiazine with a reduced dose.|Take sulfadiazine with an increased dose.	Proceed taking sulfadiazine as normal. There is no recommendation.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfadiazine. Take an alternate therapy.|Take sulfadiazine with a reduced dose.|Take sulfadiazine with an increased dose.	Proceed taking sulfadiazine as normal. There is no recommendation.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfadiazine. Take an alternate therapy.|Take sulfadiazine with a reduced dose.|Take sulfadiazine with an increased dose.	Proceed taking sulfadiazine as normal. There is no recommendation.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfadiazine. Take an alternate therapy.|Take sulfadiazine with a reduced dose.|Take sulfadiazine with an increased dose.	Proceed taking sulfadiazine as normal. There is no recommendation.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status	Avoid sulfadimidine. Take an alternate therapy.|Take sulfadimidine with a reduced dose.|Take sulfadimidine with an increased dose.	Proceed taking sulfadimidine as normal. There is no recommendation.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfadimidine. Take an alternate therapy.|Take sulfadimidine with a reduced dose.|Take sulfadimidine with an increased dose.	Proceed taking sulfadimidine as normal. There is no recommendation.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfadimidine. Take an alternate therapy.|Take sulfadimidine with a reduced dose.|Take sulfadimidine with an increased dose.	Proceed taking sulfadimidine as normal. There is no recommendation.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfadimidine. Take an alternate therapy.|Take sulfadimidine with a reduced dose.|Take sulfadimidine with an increased dose.	Proceed taking sulfadimidine as normal. There is no recommendation.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfadimidine. Take an alternate therapy.|Take sulfadimidine with a reduced dose.|Take sulfadimidine with an increased dose.	Proceed taking sulfadimidine as normal. There is no recommendation.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status	Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.|Take sulfamethoxazole / trimethoprim with a reduced dose.|Take sulfamethoxazole / trimethoprim with an increased dose.	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status at standard doses	Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.|Take sulfamethoxazole / trimethoprim with a reduced dose.|Take sulfamethoxazole / trimethoprim with an increased dose.	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfamethoxazole / trimethoprim?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.|Take sulfamethoxazole / trimethoprim with a reduced dose.|Take sulfamethoxazole / trimethoprim with an increased dose.	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status at standard doses	Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.|Take sulfamethoxazole / trimethoprim with a reduced dose.|Take sulfamethoxazole / trimethoprim with an increased dose.	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status	Avoid sulfanilamide. Take an alternate therapy.|Take sulfanilamide with a reduced dose.|Take sulfanilamide with an increased dose.	Proceed taking sulfanilamide as normal. There is no recommendation.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfanilamide. Take an alternate therapy.|Take sulfanilamide with a reduced dose.|Take sulfanilamide with an increased dose.	Proceed taking sulfanilamide as normal. There is no recommendation.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status at standard doses	Avoid sulfanilamide. Take an alternate therapy.|Take sulfanilamide with a reduced dose.|Take sulfanilamide with an increased dose.	Proceed taking sulfanilamide as normal. There is no recommendation.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfanilamide. Take an alternate therapy.|Take sulfanilamide with a reduced dose.|Take sulfanilamide with an increased dose.	Proceed taking sulfanilamide as normal. There is no recommendation.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status	Avoid sulfasalazine. Take an alternate therapy.|Take sulfasalazine with a reduced dose.|Take sulfasalazine with an increased dose.	Proceed taking sulfasalazine as normal. There is no recommendation.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfasalazine. Take an alternate therapy.|Take sulfasalazine with a reduced dose.|Take sulfasalazine with an increased dose.	Proceed taking sulfasalazine as normal. There is no recommendation.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfasalazine. Take an alternate therapy.|Take sulfasalazine with a reduced dose.|Take sulfasalazine with an increased dose.	Proceed taking sulfasalazine as normal. There is no recommendation.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status at standard doses	Avoid sulfasalazine. Take an alternate therapy.|Take sulfasalazine with a reduced dose.|Take sulfasalazine with an increased dose.	Proceed taking sulfasalazine as normal. There is no recommendation.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfasalazine. Take an alternate therapy.|Take sulfasalazine with a reduced dose.|Take sulfasalazine with an increased dose.	Proceed taking sulfasalazine as normal. There is no recommendation.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status	Avoid sulfisoxazole. Take an alternate therapy.|Take sulfisoxazole with a reduced dose.|Take sulfisoxazole with an increased dose.	Proceed taking sulfisoxazole as normal. There is no recommendation.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status at standard doses	Avoid sulfisoxazole. Take an alternate therapy.|Take sulfisoxazole with a reduced dose.|Take sulfisoxazole with an increased dose.	Proceed taking sulfisoxazole as normal. There is no recommendation.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid sulfisoxazole. Take an alternate therapy.|Take sulfisoxazole with a reduced dose.|Take sulfisoxazole with an increased dose.	Proceed taking sulfisoxazole as normal. There is no recommendation.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status at standard doses	Avoid sulfisoxazole. Take an alternate therapy.|Take sulfisoxazole with a reduced dose.|Take sulfisoxazole with an increased dose.	Proceed taking sulfisoxazole as normal. There is no recommendation.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid sulfisoxazole. Take an alternate therapy.|Take sulfisoxazole with a reduced dose.|Take sulfisoxazole with an increased dose.	Proceed taking sulfisoxazole as normal. There is no recommendation.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status	Avoid tolbutamide. Take an alternate therapy.|Take tolbutamide with a reduced dose.|Take tolbutamide with an increased dose.	Proceed taking tolbutamide as normal. There is no recommendation.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status at standard doses	Avoid tolbutamide. Take an alternate therapy.|Take tolbutamide with a reduced dose.|Take tolbutamide with an increased dose.	Proceed taking tolbutamide as normal. There is no recommendation.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tolbutamide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Avoid tolbutamide. Take an alternate therapy.|Take tolbutamide with a reduced dose.|Take tolbutamide with an increased dose.	Proceed taking tolbutamide as normal. There is no recommendation.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status at standard doses	Avoid tolbutamide. Take an alternate therapy.|Take tolbutamide with a reduced dose.|Take tolbutamide with an increased dose.	Proceed taking tolbutamide as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No recommendation	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No recommendation	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking phenytoin as normal. There is no recommendation.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Avoid phenytoin. Take an alternate therapy.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking phenytoin as normal. There is no recommendation.|Avoid phenytoin. Take an alternate therapy.	Take phenytoin with an altered dose.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No recommendation	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid phenytoin. Take an alternate therapy.|Take phenytoin with a reduced dose.|Take phenytoin with an increased dose.	Proceed taking phenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No recommendation	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No recommendation	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Proceed taking fosphenytoin as normal. There is no recommendation.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Avoid fosphenytoin. Take an alternate therapy.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No recommendation	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Proceed taking fosphenytoin as normal. There is no recommendation.|Avoid fosphenytoin. Take an alternate therapy.	Take fosphenytoin with an altered dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No recommendation	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Avoid fosphenytoin. Take an alternate therapy.|Take fosphenytoin with a reduced dose.|Take fosphenytoin with an increased dose.	Proceed taking fosphenytoin as normal. There is no recommendation.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid piroxicam. Take an alternate therapy.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Proceed taking piroxicam as normal. There is no recommendation.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid piroxicam. Take an alternate therapy.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Proceed taking piroxicam as normal. There is no recommendation.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking piroxicam as normal. There is no recommendation.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Avoid piroxicam. Take an alternate therapy.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking piroxicam as normal. There is no recommendation.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Avoid piroxicam. Take an alternate therapy.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking piroxicam as normal. There is no recommendation.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Avoid piroxicam. Take an alternate therapy.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam?	No recommendation	Avoid piroxicam. Take an alternate therapy.|Take piroxicam with a reduced dose.|Take piroxicam with an increased dose.	Proceed taking piroxicam as normal. There is no recommendation.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid pitavastatin. Take an alternate therapy.|Take pitavastatin with a reduced dose.|Take pitavastatin with an increased dose.	Proceed taking pitavastatin as normal. There is no recommendation.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid pitavastatin. Take an alternate therapy.|Take pitavastatin with a reduced dose.|Take pitavastatin with an increased dose.	Proceed taking pitavastatin as normal. There is no recommendation.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking pitavastatin as normal. There is no recommendation.|Avoid pitavastatin. Take an alternate therapy.	Take pitavastatin with an altered dose.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking pitavastatin as normal. There is no recommendation.|Avoid pitavastatin. Take an alternate therapy.	Take pitavastatin with an altered dose.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).	Proceed taking pitavastatin as normal. There is no recommendation.|Avoid pitavastatin. Take an alternate therapy.	Take pitavastatin with an altered dose.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin?	No recommendation	Avoid pitavastatin. Take an alternate therapy.|Take pitavastatin with a reduced dose.|Take pitavastatin with an increased dose.	Proceed taking pitavastatin as normal. There is no recommendation.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid pravastatin. Take an alternate therapy.|Take pravastatin with a reduced dose.|Take pravastatin with an increased dose.	Proceed taking pravastatin as normal. There is no recommendation.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid pravastatin. Take an alternate therapy.|Take pravastatin with a reduced dose.|Take pravastatin with an increased dose.	Proceed taking pravastatin as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Avoid pravastatin. Take an alternate therapy.|Take pravastatin with a reduced dose.|Take pravastatin with an increased dose.	Proceed taking pravastatin as normal. There is no recommendation.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Avoid pravastatin. Take an alternate therapy.|Take pravastatin with a reduced dose.|Take pravastatin with an increased dose.	Proceed taking pravastatin as normal. There is no recommendation.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pravastatin?	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg.	Proceed taking pravastatin as normal. There is no recommendation.|Avoid pravastatin. Take an alternate therapy.	Take pravastatin with an altered dose.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin?	No recommendation	Avoid pravastatin. Take an alternate therapy.|Take pravastatin with a reduced dose.|Take pravastatin with an increased dose.	Proceed taking pravastatin as normal. There is no recommendation.
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine?	No reason to avoid based on G6PD status	Avoid primaquine. Take an alternate therapy.|Take primaquine with a reduced dose.|Take primaquine with an increased dose.	Proceed taking primaquine as normal. There is no recommendation.
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine?	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	Proceed taking primaquine as normal. There is no recommendation.|Take primaquine with a reduced dose.|Take primaquine with an increased dose.	Avoid primaquine. Take an alternate therapy.
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine?	Avoid primaquine	Proceed taking primaquine as normal. There is no recommendation.|Take primaquine with a reduced dose.|Take primaquine with an increased dose.	Avoid primaquine. Take an alternate therapy.
primaquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking primaquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid primaquine. Take an alternate therapy.|Take primaquine with a reduced dose.|Take primaquine with an increased dose.	Proceed taking primaquine as normal. There is no recommendation.
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid primaquine. Take an alternate therapy.|Take primaquine with a reduced dose.|Take primaquine with an increased dose.	Proceed taking primaquine as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	n/a	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available.	Proceed taking rosuvastatin as normal. There is no recommendation.|Avoid rosuvastatin. Take an alternate therapy.	Take rosuvastatin with an altered dose.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.	Avoid rosuvastatin. Take an alternate therapy.|Take rosuvastatin with a reduced dose.|Take rosuvastatin with an increased dose.	Proceed taking rosuvastatin as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.	Proceed taking sertraline as normal. There is no recommendation.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Avoid sertraline. Take an alternate therapy.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.	Proceed taking sertraline as normal. There is no recommendation.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Avoid sertraline. Take an alternate therapy.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	No recommendation	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Proceed taking sertraline as normal. There is no recommendation.|Avoid sertraline. Take an alternate therapy.	Take sertraline with an altered dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	No recommendation	Avoid sertraline. Take an alternate therapy.|Take sertraline with a reduced dose.|Take sertraline with an increased dose.	Proceed taking sertraline as normal. There is no recommendation.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid simvastatin. Take an alternate therapy.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Proceed taking simvastatin as normal. There is no recommendation.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Avoid simvastatin. Take an alternate therapy.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Proceed taking simvastatin as normal. There is no recommendation.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	Proceed taking simvastatin as normal. There is no recommendation.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Avoid simvastatin. Take an alternate therapy.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	Proceed taking simvastatin as normal. There is no recommendation.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Avoid simvastatin. Take an alternate therapy.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Proceed taking simvastatin as normal. There is no recommendation.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Avoid simvastatin. Take an alternate therapy.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin?	No recommendation	Avoid simvastatin. Take an alternate therapy.|Take simvastatin with a reduced dose.|Take simvastatin with an increased dose.	Proceed taking simvastatin as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Proceed taking tacrolimus as normal. There is no recommendation.|Avoid tacrolimus. Take an alternate therapy.	Take tacrolimus with an altered dose.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Proceed taking tacrolimus as normal. There is no recommendation.|Avoid tacrolimus. Take an alternate therapy.	Take tacrolimus with an altered dose.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Proceed taking tacrolimus as normal. There is no recommendation.|Avoid tacrolimus. Take an alternate therapy.	Take tacrolimus with an altered dose.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Poor Metabolizer for CYP3A5 with regards to taking tacrolimus?	Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.	Avoid tacrolimus. Take an alternate therapy.|Take tacrolimus with a reduced dose.|Take tacrolimus with an increased dose.	Proceed taking tacrolimus as normal. There is no recommendation.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus?	No recommendation	Avoid tacrolimus. Take an alternate therapy.|Take tacrolimus with a reduced dose.|Take tacrolimus with an increased dose.	Proceed taking tacrolimus as normal. There is no recommendation.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine?	No reason to avoid based on G6PD status	Avoid tafenoquine. Take an alternate therapy.|Take tafenoquine with a reduced dose.|Take tafenoquine with an increased dose.	Proceed taking tafenoquine as normal. There is no recommendation.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine?	Avoid use	Proceed taking tafenoquine as normal. There is no recommendation.|Take tafenoquine with a reduced dose.|Take tafenoquine with an increased dose.	Avoid tafenoquine. Take an alternate therapy.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine?	Avoid use	Proceed taking tafenoquine as normal. There is no recommendation.|Take tafenoquine with a reduced dose.|Take tafenoquine with an increased dose.	Avoid tafenoquine. Take an alternate therapy.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tafenoquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid tafenoquine. Take an alternate therapy.|Take tafenoquine with a reduced dose.|Take tafenoquine with an increased dose.	Proceed taking tafenoquine as normal. There is no recommendation.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid tafenoquine. Take an alternate therapy.|Take tafenoquine with a reduced dose.|Take tafenoquine with an increased dose.	Proceed taking tafenoquine as normal. There is no recommendation.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tamoxifen?	Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).	Proceed taking tamoxifen as normal. There is no recommendation.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Avoid tamoxifen. Take an alternate therapy.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tamoxifen?	No recommendation	Avoid tamoxifen. Take an alternate therapy.|Take tamoxifen with a reduced dose.|Take tamoxifen with an increased dose.	Proceed taking tamoxifen as normal. There is no recommendation.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid tenoxicam. Take an alternate therapy.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Proceed taking tenoxicam as normal. There is no recommendation.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Avoid tenoxicam. Take an alternate therapy.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Proceed taking tenoxicam as normal. There is no recommendation.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking tenoxicam as normal. There is no recommendation.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Avoid tenoxicam. Take an alternate therapy.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking tenoxicam as normal. There is no recommendation.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Avoid tenoxicam. Take an alternate therapy.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Proceed taking tenoxicam as normal. There is no recommendation.|Take tenoxicam with a reduced dose.|Take tenoxicam with an increased dose.	Avoid tenoxicam. Take an alternate therapy.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking thioguanine?	TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Avoid thioguanine. Take an alternate therapy.|Take thioguanine with a reduced dose.|Take thioguanine with an increased dose.	Proceed taking thioguanine as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Proceed taking thioguanine as normal. There is no recommendation.|Avoid thioguanine. Take an alternate therapy.	Take thioguanine with an altered dose.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue?	No reason to avoid ased on G6PD status	Avoid toluidine blue. Take an alternate therapy.|Take toluidine blue with a reduced dose.|Take toluidine blue with an increased dose.	Proceed taking toluidine blue as normal. There is no recommendation.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue?	Avoid use	Proceed taking toluidine blue as normal. There is no recommendation.|Take toluidine blue with a reduced dose.|Take toluidine blue with an increased dose.	Avoid toluidine blue. Take an alternate therapy.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue?	Avoid use	Proceed taking toluidine blue as normal. There is no recommendation.|Take toluidine blue with a reduced dose.|Take toluidine blue with an increased dose.	Avoid toluidine blue. Take an alternate therapy.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking toluidine blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid toluidine blue. Take an alternate therapy.|Take toluidine blue with a reduced dose.|Take toluidine blue with an increased dose.	Proceed taking toluidine blue as normal. There is no recommendation.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Avoid toluidine blue. Take an alternate therapy.|Take toluidine blue with a reduced dose.|Take toluidine blue with an increased dose.	Proceed taking toluidine blue as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol?	No recommendation	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Avoid tramadol. Take an alternate therapy.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Proceed taking tramadol as normal. There is no recommendation.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Proceed taking tramadol as normal. There is no recommendation.|Take tramadol with a reduced dose.|Take tramadol with an increased dose.	Avoid tramadol. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Avoid trimipramine. Take an alternate therapy.	Take trimipramine with an altered dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole?	No recommendation	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.	Avoid trimipramine. Take an alternate therapy.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Proceed taking trimipramine as normal. There is no recommendation.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Proceed taking trimipramine as normal. There is no recommendation.|Take trimipramine with a reduced dose.|Take trimipramine with an increased dose.	Avoid trimipramine. Take an alternate therapy.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking venlafaxine?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Proceed taking venlafaxine as normal. There is no recommendation.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Avoid venlafaxine. Take an alternate therapy.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking venlafaxine?	No recommendation	Avoid venlafaxine. Take an alternate therapy.|Take venlafaxine with a reduced dose.|Take venlafaxine with an increased dose.	Proceed taking venlafaxine as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Proceed taking voriconazole as normal. There is no recommendation.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Avoid voriconazole. Take an alternate therapy.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole?	No recommendation	Avoid voriconazole. Take an alternate therapy.|Take voriconazole with a reduced dose.|Take voriconazole with an increased dose.	Proceed taking voriconazole as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Proceed taking vortioxetine as normal. There is no recommendation.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Avoid vortioxetine. Take an alternate therapy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking vortioxetine?	Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Proceed taking vortioxetine as normal. There is no recommendation.|Avoid vortioxetine. Take an alternate therapy.	Take vortioxetine with an altered dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking vortioxetine?	No recommendation	Avoid vortioxetine. Take an alternate therapy.|Take vortioxetine with a reduced dose.|Take vortioxetine with an increased dose.	Proceed taking vortioxetine as normal. There is no recommendation.
